Hemp Inc (OTCMKTS: HEMP) has struggled for direction after coming under immense bearish pressure, resulting in a 50% slide. In recent weeks, the stock has resorted to trading in a tight trading range of between $0.02 and $0.03, on the lack of catalysts to fuel the upward momentum. However, not anymore.
HEMP Catalysts And Price Analysis
A confirmation that the Company registered an 1800% increase in sales for the full year ended December 31, 2018, could as well be the catalyst to fuel a bounce back from current lows. The steady increase underlines underlying growth at a time when demand for cannabis products is on the rise.
The Company has also provided a 2019 outlook that underscores expected growth as management focuses attention and resources to transforming Hemp Inc. into a full-blown marketing entity.
With the stock currently, trading at the $0.02 level, a rally could be in the offing given the formation of a bullish spiking channel. The formation of higher lows in recent weeks signals a stock due for a correction higher as a bounce-back play.
The $0.03 mark is the immediate resistance level standing in the way of the stock spiking high in continuation of the emerging uptrend. Hemp finding support above the $0.03 level should open the door for it to make a run for the $0.04 mark, the next critical resistance level.
Above the $0.04 level, the stock would be well positioned to continue rallying on improved underlying fundamentals.
What Does Hemp Do?
Hemp is engaged in the production of products made from industrial hemp. The Company boasts of one of the largest commercial multi-purpose industrial hemp processing facility in North America. It also provides products and services to the medical and recreational marijuana industries.
Sales Growth Boost
Hemp Inc. delivering full-year sales of $1.96 million in 2018 up from 107,002 generated in 2017 is a milestone achievement that underscores robust growth. The 1800% year over year increase highlights the Company’s foothold in the highly competitive industry.
Chief Executive Officer, Bruce Perlowin, attributes the robust sales growth to the building of solid hemp infrastructure that was not inexistent in the previous years.
“We’ve invested heavily to build this infrastructure, which currently consists of 9 divisions, as you’ll read below. I liken Hemp, Inc.’s business model to that of the Amazon.com model where today the richest man in the world plowed all their operating capital and profits back into building the infrastructure. “We’re hitting the market hard with massive revenues generated from massive sales,” explained Mr. Perlowin.
In a bid to accelerate sales growth in the second half of the year, the management intends to focus on strengthening marketing operations instead of building a massive infrastructure. By focusing on marketing, the management intends to transform Hemp Inc. into an operating company from a developmental stage company.
Enhancing Hemp Production And Marketing
Hemp Inc. remains well positioned to make good use of the growing demand for cannabis products in the market, at the back of the ongoing evolution. The Company boasts of two hemp-processing facilities. One of the facilities located in Spring Hope North Carolina us ranked as one of the largest hemp-processing center in the western hemisphere.
The North Carolina facility is operating full time, processing millions of pounds of unique kenaf used in the manufacture of all green natural loss circulation materials. The Company is also in the process of building two other production facilities in a bid to ramp up production capacity.
In addition to ramping up production, Hemp Inc. is also enhancing its marketing operations in a bid to cater to the growing needs of the cannabis market, poised to reach $22 billion by 2022. The Company has so far formed a joint venture with retail store Hemp Healthcare in Dolan Springs Arizona to sell high-quality cannabidiol as well as hemp-based products.
Hemp Inc has been under immense short selling pressure if a 50% plus slide since the start of the year is anything to go by. The slide has come even on the broader cannabis sector trending higher after a roller coaster 2018. However, the stock appears to have hit bottom and due for a correction higher.
The Company reporting an 1800% year-over-year increase in sales is a development that should continue to strengthen the stock’s sentiments in the market. For investors eyeing opportunities in the stock then it might be wise to wait for the stock to rally and find support above the $0.03 mark.
For the latest updates on HEMP and other HEMP stocks, sign up below!
Disclosure: We have no position in HEMP and have not been compensated for this article.
Forget APHA and ACB, Buy GTBIF and TCNNF
There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).
On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.
There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.
The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…